Company intelligence / Profile preview
Carmel Biosciences
Atlanta, Georgia, USAcarmelbio.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
- Focuses on cardiovascular/metabolic therapies through small molecules and reformulation tech
- Developed first FDA-approved oral liquid valsartan formulation (2017)
- Maintains preclinical pipeline of lipid modulators for cardiovascular diseases
- Therapeutic areas
- Cardiovascular
- Modalities
- Small molecule drugOral solutions
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Carmel Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carmel Biosciences.